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Abstract
Background: Dendritic cells (DCs) have been used as vaccines in clinical trials of immunotherapy of cancer and other
diseases. Nonetheless, progress towards the use of DCs in the clinic has been slow due in part to the absence of standard
methods for DC preparation and exposure to disease-associated antigens. Because different ex vivo exposure methods
can affect DC phenotype and function differently, we studied whether electroporation-mediated transfection
(electrotransfection) of myeloid DCs with in vitro expanded RNA isolated from tumor tissue might be feasible as a
standard physical method in the preparation of clinical-grade DC vaccines.
Methods: We prepared immature DCs (IDCs) from CD14+ cells isolated from leukapheresis products and extracted
total RNA from freshly resected melanoma tissue. We reversely transcribed the RNA while attaching a T7 promoter to
the products that we subsequently amplified by PCR. We transcribed the amplified cDNA in vitro and introduced the
expanded RNA into IDCs by electroporation followed by DC maturation and cryopreservation. Isolated and expanded
mRNA was analyzed for the presence of melanoma-associated tumor antigens gp100, tyrosinase or MART1. To test
product safety, we injected five million DCs subcutaneously at three-week intervals for up to four injections into six
patients suffering from stage IV malignant melanoma.
Results: Three preparations contained all three transcripts, one isolate contained tyrosinase and gp100 and one
contained none. Electrotransfection of DCs did not affect viability and phenotype of fresh mature DCs. However, post-
thaw viability was lower (69 ± 12 percent) in comparison to non-electroporated cells (82 ± 12 percent; p = 0.001). No
patient exhibited grade 3 or 4 toxicity upon DC injections.
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Conclusion: Standardized preparation of viable clinical-grade DCs transfected with tumor-derived and in vitro amplified
mRNA is feasible and their administration is safe.
Background
Dendritic cells (DCs) have been used in numerous recent
clinical trials as vaccines intended to break tolerance to
tumors and induce tumor-specific therapeutic immunity
[1]. To break tolerance to the tumor, DCs must effectively
present tumor-associated antigen(s). Antigens have been
delivered to DC as whole-tumor lysates, natural or syn-
thetic peptides, recombinant viruses, tumor specific RNA,
and recombinant DNA [2]. Most of these sources have
been used for clinical trials, particularly tumor lysates;
however, tumor lysates are a limited and inconsistent
source of antigenic material. The optimal method for anti-
gen delivery to DCs is still controversial [2].
A current discussion of antigen delivery to DCs concluded
that "the most constitutive and prolonged MHC I presen-
tation would likely result from processing of endog-
enously produced proteins located in the cytoplasm; like
other cells, DC present self- or virus-derived endogenous
antigens generated via proteasome degradation of newly
synthesized ubiquitinated proteins" [3]. These require-
ments limit the choice of antigen delivery to viral con-
structs, DNA or RNA. Among these options, delivery of
tumor-derived RNA has been the most reliable, and effi-
cient as it induced the highest level of immunity [4-6].
Delivery of RNA containing entire protein coding
sequences eliminates the need to select patients on the
basis of their HLA antigens, a restriction characteristic of
the use of antigenic peptides.
In our efforts to contribute to the development of DC-
based vaccination strategies for immunotherapy, others
and we are studying metastatic malignant melanoma.
Metastatic melanoma is an incurable condition with a
median survival time of nine months and a less than 5
percent likelihood of survival five years following diagno-
sis [7] with a continuing increase in age-adjusted mortal-
ity [8]. One of the most intriguing investigational
approaches to melanoma therapy has been immuno-
therapy [9]. Driven in part by anecdotal reports of sponta-
neous resolution of metastases and broad resistance to
numerous conventional chemotherapy agents, immuno-
therapy of melanoma has been the focal point of clinical
cancer immunotherapy [10-13]. DC vaccines have been
studied for their ability to recruit naïve T cells and stimu-
late tumor-specific memory T cells for induction of clini-
cal responses [1,14]. Despite some progress, the clinical
efficacy of therapeutic DC vaccines remains unpredicta-
ble. The absence of significant and predictable clinical
responses has been ascribed in part to the lack of a stand-
ardized approach to DC preparation, treatment regimens
and outcome measurements [2,15].
To develop a standardized method of preparing a clinical-
grade myeloid DC vaccine for treatment of malignant
melanoma, we explored the use of electroporation-medi-
ated transfection (electrotransfection) as a method ame-
nable to standardization of physical variables. In
addition, we employed ex vivo amplification of autolo-
gous tumor-derived mRNA [16,17] as it allows a level of
standardization of the process and final product. Electro-
poration has been validated in numerous laboratory stud-
ies [6,18-21] and has been used for transfection of
unexpanded tumor-derived RNA [21]. Here we report our
experience in preparing clinical-grade myeloid DCs by
electrotransfection of in vitro amplified tumor-derived
mRNA and safety testing of the DC product in patients
suffering from stage IV malignant melanoma.
Methods
Dendritic cell vaccine preparation
The overall scheme of DC vaccine preparation included
separation of IDCs from autologous CD14-positive cells
and isolation of total RNA from autologous tumor tissue.
RNA was reversely transcribed to obtain cDNA and ampli-
fied using cDNA as template incorporating a T7 RNA pro-
moter. Amplified cDNA was in vitro transcribed and
loaded into IDCs by electroporation. The DCs were subse-
quently matured in the presence of inflammatory
cytokines and cryopreserved as single aliquots prior to
use.
Dendritic cells
Mononuclear cell were collected from patients by conven-
tional leukapheresis. The collected cells were incubated
with clinical-grade CD14-specific immunomagnetic rea-
gent (Miltenyi Biotec, Auburn, CA) and separated on a
CliniMACS apparatus (Miltenyi) using Enrichment 1.1
program. The cells were further processed by the previ-
ously described method [22,23] in a Class 10,000 cGMP-
grade cell processing facility equipped with Class-100 bio-
logical safety cabinets for aseptic manipulation. Briefly,
CD14+ cells were plated in polystyrene flasks at 2 × 106
cells/mL in X-VIVO 15 medium (BioWhittaker, Walkers-
ville, MD) containing 1.0 percent pooled human AB
serum (HABS; C-6 Diagnostics, Mequon, WI) GM-CSF
(800 IU/mL, Immunex, Seattle, WA) and IL-4 (1000 IU/
mL, R&D Systems, Minneapolis MN). The flasks were
incubated at 37°C in a humidified atmosphere of 5 per-
cent CO2. One mL of the same medium, but with GM-CSFJournal of Translational Medicine 2006, 4:35 http://www.translational-medicine.com/content/4/1/35
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increased to 1600 IU/mL, was added per three mL of the
medium three and five days later, respectively. On the sev-
enth day non-adherent cells were collected and resus-
pended in the electroporation medium and
electrotransfected with in vitro amplified tumor-derived
RNA (see below). RNA-loaded DCs were resuspended at
1.0 × 106/mL in X-VIVO 15, 1.0 percent HABS, 800 IU/mL
GM-CSF, 1000 IU/mL IL-4, 1100 IU/mL TNF-α, 1870 IU/
mL and 1.0 µg/mL prostaglandin E2 (PGE2). Non-adher-
ent MDCs were collected two days later, tested for sterility,
viability, and phenotype (by expression of CD14, CD83
and CD86). DC products were predominantly CD14-neg-
ative (12 ± 6 percent of cells were CD14low), CD86high (96
± 2 percent) and mature (80 ± 6 percent CD83+), in accord
with our earlier experience [23]. For a more detailed char-
acterization, we measured also the expression of HLA-A,
B, C, HLA-DR, CD40, CD54, CD80, CD209 and CCR7 in
DCs from Patient 1 and Patient 5.
Cell characterization by flow cytometry
We characterized the cells by flow cytometry with a FACS-
Calibur flow cytometer (BD Biosciences, San Jose, CA)
and the fluorophore-conjugated monoclonal antibodies
with specificity indicated in Table 1. For each analysis we
recorded one hundred thousand counts. Data were ana-
lyzed with CellQuest software (BD Biosciences).
Tumor RNA extraction
Tumor tissues were surgically resected, aseptically col-
lected, and immediately transported to the cell processing
facility. Fresh tissue was cut into cubes measuring approx-
imately 3 × 3 × 3 mm. Each piece was placed into a sepa-
rate 1.5 mL RNase-free tube and covered with RLT buffer
(Qiagen, Valencia, CA). Tissues were homogenized with
the Pellet Pestle™ (Kontes, Vineland, NJ). To each sample
100 µL of RNase-free water and 350 µL of RLT buffer (con-
taining 10 µL β-mercaptoethanol per mL of RLT buffer)
were added and the sample was briefly vortexed and
quickly centrifuged. Then 250 µL of 96 percent ethanol
was added and thoroughly mixed by pipetting. The sam-
ple viscosity was reduced using a Qiashredder (Qiagen)
and 700 µL was applied onto an RNeasy™ mini column
(Qiagen) as directed by the manufacturer. Purified total
RNA was collected in 50 µL of RNase-free water. RNA was
quantified photometrically at 260 nm using  the extinc-
tion coefficient of 0.025 for a 1.0 µg/mL solution and its
integrity was monitored by agarose gel electrophoresis
and in some cases confirmed by the use of an Agilent Bio-
analyzer™ (Agilent Technologies, Palo Alto, CA) at the
Mayo Clinic Microarray Core Facility. A sample was
acceptable for further use if it contained more than 2.5 µg
of RNA.
Reverse transcription and RNA amplification
Autologous tumor RNA was amplified and prepared for in
vitro transcription as described by others [24]. Briefly, 2.5
µg of total tumor RNA per reaction was incubated with the
first strand primer (5'-AAGCAGTGGTATCAACGCAGAG
TACT(30)VN-3'; where V is G, A, or C and N is any nucle-
otide) and the dNTP mixture at 65°C for 5 min and 8°C
for 10 min [24]. We then added DTT, the reaction buffer,
RNaseOUT (Invitrogen, Carlsbad, CA) and Superscript II
reverse transcriptase (Invitrogen) and reversely tran-
scribed the RNA at 42°C for 35 min. Then 10 pmol of the
T7 Switch primer (5'-CTAATACGACTCACTATAGGGCGG
G-3') was added and the solution was further incubated at
42°C for 30 min, at 70°C for 15 min and 42°C for 2 min.
The resulting cDNA (2 µL per reaction) was used as tem-
plate for a 100-µL PCR reaction using the Advantage™
polymerase (Clontech, Mountain View, CA) according to
the manufacturer's directions with 20 pmol of the T7-5'
(5'CCATCCTAATACGACTCACTATAG-GGC-3'), and T7-
3' (5'-AAGCAGTGGTATCAACGCAGAGT-3') as primers.
PCR included one cycle at 95°C for 1 min; 25 cycles of
95°C for 15 sec, 65°C for 20 sec and 68°C for 6 min; and
the final incubation at 68°C for 7 min. All primers were
synthesized at the Mayo Clinic DNA Synthesis Core Facil-
ity.
To transcribe the RNA in vitro, for each reaction we added
sequentially the following reagents to a RNase-free tube at
room temperature: RNase-free water to bring the final vol-
ume to 20 µL, 10 µL 2× NTP/CAP, 2 µL 10× buffer, 1 µg
cDNA, and 2 µL mMessage mMachine RNA polymerase
mix (Ambion, Austin, TX). Typically, we performed five to
15 reactions per sample. After in vitro transcription the
individual reaction products were pooled, and excess
nucleic acids and primers removed by gel filtration using
a NucAway spin column (Ambion) centrifuged at 750 × g
for 2 min. The tube containing the bulk of the RNA was
frozen and stored at -70°C. Aliquots were analyzed for
RNA quantity and integrity by agarose gel electrophoresis
and/or capillary microelectrophoresis by use of the Agi-
lent Bioanalyzer 2100.
Table 1: Immunoreagents used in this study
Antibody specificity Fluorescent label Manufacturer
HLA-ABC PEa BD Pharmingen
HLA-DR FITC Biosourceb
CD14 PE eBioscience
CD40 FITC BD Pharmingen
CD54 PE Biosource
CD80 FITC BD Pharmingen
CD83 PE Immunotechc
CD86 FITC Ancell d
CD209 FITC eBioscience
CCR7 FITC R&D Systems
IgG PE Biosource
a FITC, fluorescein isothiocyanate; PE, phycoerythrin; APC, 
allophycocyanin; b Camarillo, CA; c Miami, FL; d Bayport, MN.Journal of Translational Medicine 2006, 4:35 http://www.translational-medicine.com/content/4/1/35
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(A) Size distribution of nucleic acids obtained during processing Figure 1
(A) Size distribution of nucleic acids obtained during processing. Nondenaturing agarose gel electropherograms 
showing the size distribution of total RNA extracted from the tumor (R), cDNA after reverse transcription (C), amplified 
cDNA (aC) and in vitro transcribed RNA (iR). rL stands for RNA marker ladder (gel 3) and N for negative control. Upper 
arrow at the DNA marker ladder (dL) points to the band of 3 kb and the lower arrow to the band of 1 kb. Numbers refer to 
patients 1 to 6. (B) Capillary microelectropherograms of total RNA isolated from tumor tissue (upper row) and 
the corresponding in vitro transcribed RNA (lower row). RNA samples from patient 2 are represented on the left and 
samples from patient 6 on the right. The sharp peak at the left of each plot is a loading control. The two other prominent peaks 
in the upper plots represent ribosomal RNA.
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Dendritic cell electrotransfection with RNA
For experiments aimed at optimizing electroporation con-
ditions, a cDNA encoding the enhanced green fluorescent
protein (eGFP) gene and containing a T7 promoter and
polyadenylation signal suitable for DC transfection was
generously provided by S. Sæbøe-Larssen, University of
Oslo, Oslo, Norway, and prepared as described in ref.
[18]. The plasmid served as template for in vitro transcrip-
tion using mMESSAGE mMACHINE kits (Ambion, Aus-
tin, TX). The transcription reaction mixture was purified
using Nuc Away spin columns (Ambion) according to
manufacturer's instruction. Concentration of the resulting
mRNA was measured photometrically at 260 nm and 280
nm. For transfection into DCs, mRNA was dissolved in
water at 1.0 mg/mL.
Immature DCs manufactured from the blood of
melanoma patients were electrotransfected with mRNA
isolated from autologous tumor tissue and in vitro ampli-
fied [24]. The cells were prepared as above except that the
IDCs were washed, suspended in the Cytoporation For-
mula R Medium (Cyto Pulse Sciences, Inc., Glen Burnie,
MD) at a density of 1 × 107/mL in the presence of 20–50
µg/mL of autologous mRNA. The cell suspension was
transferred to sterile, disposable electroporation cuvettes
with a 4-mm electrode gap (Molecular BioProducts, San
Diego, CA). The cells were subjected to two square 400-V
pulses of 50 µs each from the PA-4000 PulseAgile genera-
tor. Following electroporation the cells were rested in X-
VIVO 15 medium containing HABS, GM-CSF and IL-4 as
above at 37°C in humidified 5 percent CO2 for one hour.
Subsequently the cells were washed once and suspended
in the maturation medium containing 1100 IU/mL TNF-
α and 1.0 µg/mL PGE2 for two more days. MDCs were col-
lected, assayed for compliance with release criteria and
administered as described above. All vaccines were frozen
and thawed prior to administration.
Melanoma-specific transcripts in amplified mRNA
Total RNA was extracted from patients' melanoma tissues
and from cell lines Sk-mel 28 (HTB-72, American Type
Culture Collection, Manassas, VA) and T2 cells (CRL-
1992, American Type Culture Collection) as positive and
negative control, respectively. RNA samples were tested
before and after in vitro expansion for the presence of tran-
scripts of tumor-associated molecules gp100, tyrosinase,
and Mart1 and of G6PDH (as positive control). Briefly, 1
µg of RNA was used as a template in a 50-µL single-tube
RT-PCR reaction using Titan RT-PCR (Roche Diagnostics,
Indianapolis, IN), one set of primers, and 30 cycles of PCR
according to manufacturer's directions. Primer sequences
and predicted amplicon sizes are indicated in Table 2.
Products of each reaction were analyzed by electrophore-
sis on ethidium-bromide-stained 1.0 percent agarose gel
and scored for the presence or absence of the transcript.
Clinical protocol
This trial enrolled six patients who were at least 18 years
of age with histologically proven stage IV malignant
melanoma. Three patients met the RECIST criteria for
measurable disease [25], two had evaluable disease only
and one patient had resected metastatic disease and was
followed for progression. Contraindications to study
entry included: unsatisfactory hematologic or blood
chemistry profile (defined as absolute neutrophil count
below or equal to 1,500/mL, platelet count below or
equal to 100,000/mL, hemoglobin below 9.0 g/dL, serum
alkaline phosphatase three times above the institutional
upper limit of normal (ULN), aspartate transferase three
times above ULN or creatinine 1.5 times above ULN, life
expectancy of less than 12 weeks, ECOG performance sta-
tus of 3 or 4, uncontrolled infection, prior immunization
with differentiation antigen peptides, recent chemother-
apy/immunotherapy/radiation therapy (less than one
month prior to registration), known central nervous sys-
tem metastases or carcinomatous meningitis, seizure dis-
order, active psychiatric disorder requiring pharmacologic
therapy, known immune deficiency, history of other
malignancies within the last five years, and inability to
provide informed written consent. Women of childbear-
ing potential were required to have a serum pregnancy test
at most seven days prior to registration. Women of child-
bearing age who were unwilling to employ adequate con-
Table 2: Primer sequences and predicted amplicon sizes in detection of melanoma-specific transcripts in dendritic cells
Transcript Sequence Predicted amplicon size (bp) Ref.
GAPDH GAA GGT GAA GGT CGG AGT C 226 [29]
GAPDH GAA AGA TGG TGA TGG GAT TC
Mart1 Out1 ATG CCA AGA GAA GAT GCT CAG 384
Mart1 Out2-2 AGC ATG TCT CAG GTG TCT CG
gp100 Out1 GCT TGG TGT CTC AAG GCA ACT 751 [30]
gp100 Out2-2 CTC CAG GTA AGT ATG AGT GAC
Tyrosinase Out1 TTG GCA GAT TGT CTG TAG CC 284
Tyrosinase Out2-2 AGG CAT TGT GCA TGC TGC TTJournal of Translational Medicine 2006, 4:35 http://www.translational-medicine.com/content/4/1/35
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traception, pregnant women, and women who were
nursing were not eligible.
Following registration, patients underwent surgical resec-
tion of a symptomatic tumor mass followed by a single
leukapheresis on average 29 days later (range: 18 to 40
days). Upon generation of the DC vaccine and recovery
from surgery, patients underwent a series of four subcuta-
neous injections of the DC vaccine (5 × 106 cells/treat-
ment) administered once every three weeks.
Intra-patient dose modifications were not allowed. If at
the time of re-treatment a patient had a grade 3 or 4 non-
hematologic toxicity or grade 2 bronchospasm, general-
ized allergic reaction or autoimmune reaction, all further
study treatments were discontinued.
Prior to each cycle of treatment and at the time of progres-
sion, patients underwent a physical examination, toxicity
assessment using the NCI common toxicity criteria [26],
evaluation of injection site skin reaction, and complete
blood count and serum chemistry profiling. Tumors were
to be assessed according to RECIST criteria at weeks 6 and
12 after treatment initiation and every three months
thereafter for up to two years. In this HLA-unrestricted
study, measurements of T cell function included vaccine-
stimulated proliferation in vitro and levels of intracellular
and secreted IFN-γ during and after treatment.
Clinical study end-points
The principal end-point of this study included the deter-
mination of the safety and toxicity profile of the mRNA-
transfected autologous DC vaccine administered to
patients with stage IV melanoma. Although the clinical
status of the patients made the expectations for major
immune and/or clinical effects of treatment unlikely, our
secondary end-points included a description of immuni-
zation efficacy of the vaccine and the collection of prelim-
inary descriptive data of clinical efficacy (tumor
responses, progression free survival and overall survival)
of the DC vaccine.
Six patients were accrued to the study. Enrollment was to
be suspended if two or more of the six patients experi-
enced a grade 4 hematologic toxicity lasting five or more
days or a rise in serum creatinine of two or more times
above the pretreatment value. All patients who fulfilled
the eligibility criteria and received one injection were
included in all analyses. Tumor response rate was esti-
mated on the number of eligible patients who achieved a
complete or partial remission on two consecutive evalua-
tions divided by the total number of eligible patients
enrolled.
Immune response monitoring
Peripheral blood was drawn before the first DC vaccina-
tion, after the third vaccination and one month after the
fourth and final vaccination when possible. We isolated T
cells by negative immunomagnetic adsorption (Miltenyi)
and cryopreserved them until they could be analyzed in a
single experiment after the completion of the trial. In
addition, we compared the mRNA-transfected DCs with
DCs that were not electroporated for the ability to stimu-
late proliferation of and IFN-γ secretion by T cells.
Measuring IFN-γ secretion by ELISpot
We coated 96-well plates (Multiscreen; Millipore, Bed-
ford, MA) with the capture monoclonal antibody specific
for human IFN-γ (1:500 dilution, eBioscience, San Diego,
CA) overnight at 4°C. Plates were further incubated with
blocking solution (X-VIVO 15 supplemented with 10 per-
cent Human AB serum and 1.0 percent penicillin/strepto-
mycin solution), 200 µL per well, for two hours at room
temperature. T cells were seeded in quadruplicate wells in
a tenfold excess over mRNA-transfected or mock-trans-
fected DCs in X-VIVO 15 supplemented with 1.0 percent
human AB serum and 1.0 percent penicillin/streptomy-
cin. Alternatively, the DCs were incubated with Fluzone®
influenza virus vaccine (2005–2006 formula; Aventis Pas-
Table 3: Isolated total RNA mass and volume, mass of cDNA after PCR amplification and the corresponding data for RNA amplified by 
in vitro transcription together with amplification factors for each step and overall amplification
Pt No. Total RNA 
volume (µL)
Total RNA 
mass (µg)
Amplified 
cDNA (µg)
PCR 
amplification 
factor
Amplified 
RNA 
volume (µL)
[Amplified 
RNA] (µg/
µL)
Transcription 
amplification 
factor
Overall 
amplification 
factora
1 40 15.7 63.5 15.9 400 31.1 195 3100
2 90 30.4 74.0 18.5 1000 2.1 27 500
3 100 10.4 51.9 9.9 2013 1.8 70 700
4 35 15.8 75.1 10.7 1471 2.2 44 500
5 155 78.9 63.2 9.0 1320 5.2 109 1000
6 40 20.2 99.0 14.1 1592 1.7 37 500
Avg 76.67 28.6 71.1 13.0 1299 7.4 81 1100
SD 47.75 25.5 16.1 3.8 552 11.7 63 --
aRounded to the nearest hundred.Journal of Translational Medicine 2006, 4:35 http://www.translational-medicine.com/content/4/1/35
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teur, Swiftwater, PA), 5.0 µL/mL, for two hours and
washed prior to plating. Cell cultures were incubated in a
humidified incubator with 5 percent CO2 at 37°C for 48
hours. Plates were incubated with the biotinylated IFN-γ-
detection antibody (1:500 dilution; eBioscience) for two
hours at room temperature, washed, and incubated for
one hour with avidin-HRP (eBioscience), diluted 1:1000
in PBS containing 1% Human AB serum and washed.
Then 100 µL of substrate 3-amino-9-ethylcarbazole (AEC)
solution (BD Biosciences, San Diego, CA) was added per
well. Spots were allowed to develop for 30 minutes,
washed with water and enumerated by an ImmunoSpot
plate reader (Cellular Technology, Ltd., Cleveland, OH).
Mixed lymphocyte reaction
We evaluated the ability of MDCs to stimulate T cell pro-
liferation and the proliferation capacity of T cells by mixed
lymphocyte reaction (MLR). MDCs from melanoma
patients and four normal subjects were added each at 1.0
× 104 per well in 96-well plates containing X-VIVO 15
medium supplemented with 1.0 percent HABS and 1.0
percent penicillin/streptomycin. One hundred thousand
T cells mixed from four healthy donors in equal propor-
tions were added to each well containing the MDCs in a
final volume of 200 mL. The cells were co-incubated for
84 hours. Twelve hours prior to cell collection with a Ska-
tron (Sterling, VA) semiautomatic cell harvester, [3H]-thy-
midine (1.0 µCi in 100 µL) was added to each well.
Radioactivity incorporated into DNA was measured by a
LS 6000SC (Beckman-Coulter, Fullerton, CA) scintillation
counter. To evaluate the capacity of individual T cells from
the patients and healthy controls, we followed the same
procedure except that we used a mixture of equal propor-
tions of MDCs from four healthy donors.
Statistical analysis
Differences among characteristics of DC data groups were
assessed by the two-tailed t-test for independent samples
with equal variance. All data sets contained measurements
from each of the six patients (n = 6). In all analyses we
used Prism 4.0 software (GraphPad, San Diego, CA) for
Macintosh computers.
Results
Feasibility of preparing autologous tumor-mRNA 
transfected DC vaccines
The primary laboratory goal of this study was to evaluate
the feasibility of constructing a clinical grade autologous
cancer vaccine using autologous DCs transfected with in
vitro  amplified tumor mRNA. RNA was extracted and
amplified as specified above. Pertinent data documenting
the efficiency of cDNA amplification and in vitro transcrip-
tion are shown in Table 3. The total amplification factor
(e.g., how many times RNA isolated from the tumor has
been amplified before used for transfection) is calculated
as the product of the PCR amplification factor and the
transcription amplification factor. Total masses and vol-
umes are those entered into the respective amplification
step, not the total amount isolated from the tumor.
For all patients we monitored cDNA amplification and in
vitro transcription by gel electrophoresis (Figure 1A) and
for patients 2 and 6 by capillary microelectrophoresis
(Figure 1B). We found that the total RNA extracted from
tumors consistently displayed the characteristic RNA,
ribosomal RNA and cDNA species up to 5 kb in length
throughout the entire process (Figure 1A, B). Further-
more, in total RNA and in vitro transcribed RNA we mon-
itored the presence of melanoma-specific transcripts
gp100, tyrosinase, and MART1 by RT-PCR (Table 4). In
only one in vitro amplified sample we could not detect a
transcript that was present in the total RNA. Thus, the
process had sufficient fidelity to maintain the presence of
the monitored melanoma-specific transcript throughout
in vitro amplification.
Optimization of DC electrotransfection with in vitro 
amplified mRNA
We optimized electrotransfection by monitoring transfec-
tion efficiency and DC viability as a function of electrode
separation, pulse amplitude and length and amplified
mRNA concentration in the medium. In all experiments
we employed a PA-4000 PulseAgile square-wave genera-
tor and the proprietary cGMP-grade low-conductivity (80
µS/cm) Cytoporation Medium Formula R medium (both
Cyto Pulse Sciences, Glen Burnie, MD). We transfected
IDCs with mRNA encoding the eGFP gene, matured the
cells for 48 hours and measured transfection efficiency (by
eGFP fluorescence) and viability (by exclusion of 7-
amino-actinomycin D, 7-AAD; Pharmingen, San Diego,
CA) following transfection in electroporation cuvettes
with a 1-mm electrode separation (100 µL volume) and a
4-mm electrode separation (400 µL). With the pulse
sequence consisting of two rectangular 1.0-kV/cm 50-µs
pulses separated by 500 ms in all experiments (as recom-
Table 4: Melanoma markers present (+) or absent (-) in native 
tumor RNA and in vitro amplified RNA from patients and from 
cell lines Sk-Mel (positive control) and T2 (negative control)
Name GAPDH gp100 Tyrosinase MART1
Sk-Mel ++ + +
T2 +a - -
Patient 1 +/+ +/+ +/+ +/+
Patient 2 +/+ +/+ +/+ +/+
Patient 3 +/+ -/- -/- -/-
Patient 4 +/+ +/+ +/+ +/+
Patient 5 +/+ +/± +/+ -/-
Patient 6 Not determined
a IndeterminateJournal of Translational Medicine 2006, 4:35 http://www.translational-medicine.com/content/4/1/35
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mended by the manufacturer), we found no difference in
transfection efficiency and post-electrotransfection viabil-
ity (both being above 90 percent in both cuvettes). Thus,
for higher throughput we used the larger cell throughout
the study.
To refine the electrotransfection conditions further, we
iteratively measured the transfection efficiency and DC
viability under different parameter combinations. In the
final iteration we varied the mRNA concentration
between 4.0 µg/mL and 25 µg/mL, pulse amplitude
between 0.5 kV/cm and 2.5 kV/cm and pulse width
between 0.05 µs and 0.45 µs. From the dependence of
transfection efficiency and viability on mRNA concentra-
tion (Figure 2A), we optimized the effect of pulse ampli-
tude for mRNA concentration in the 20–25 µg/mL range
(Figure 2B). Because the pulse of 1.0 kV/cm resulted in
acceptable transfection efficiency and reasonable viability,
we further studied the effect of pulse width at 20–25 µg/
mL RNA and 1.0 kV/cm (Figure 2C). Based on these data,
we selected 1.0-kV/cm 150-µs pulses and 10 µg amplified
RNA per one million cells as an optimal compromise of
parameters for DC manufacturing.
Electrotransfected DCs translate exogenous mRNA
Determination if electrotransfected DCs can translate
exogenous transcripts may be complicated by low levels
of a transcript in the total mRNA, low levels of the result-
ing protein, high DC capacity for protein degradation and
by the consequent need for very sensitive detection tech-
niques. To mitigate these problems, we monitored expres-
sion of the transfected eGFP-mRNA; GFP is uniquely
stable within cells (cf. ref. [27]) and its presence can be
Electrotransfected dendritic cells can express transfected  mRNA Figure 3
Electrotransfected dendritic cells can express trans-
fected mRNA. IDCs, 1.0 × 107 cells/mL, were electropo-
rated by two 1.0-kV/cm 50-µs pulses separated by 500 ms in 
the presence of 20 µg eGFP-mRNA per 1.0 × 106 cells, 
matured for three days when fluorescence due to eGFP was 
quantified by flow cytometry. Dotted line: control cells elec-
troporated without mRNA; full line, the cells electroporated 
in the presence of eGFP-mRNA. Shown is a histogram typical 
of four experiments.
Identifying conditions for electrotransfection of immature  dendritic cells Figure 2
Identifying conditions for electrotransfection of 
immature dendritic cells. Normal IDCs were electro-
transfected with in vitro transcribed eGFP-mRNA. Following 
electrotransfection, the cells were matured for 48 hours 
when viability (open symbols) and transfection efficiency 
(closed symbols) were quantified (by 7-AAD exclusion and 
eGFP fluorescence, respectively). Shown are the data from 
the final iteration in the analysis where mRNA concentration 
varied from 4.0 µg/mL to 25 µg/mL (A), pulse amplitude from 
0.5 kV/cm to 2.5 kV/cm (B) and pulse width from 0.05 µs to 
0.45 µs (C). Symbols denote mean values of measurements in 
cells from three or more individuals ± standard deviation 
(except in panel C that is an example of an entire experiment 
conducted with cells from one individual).
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detected by fluorescence. We transfected IDCs, 1.0 × 107
cells/mL, in the presence of 20 µg eGFP-mRNA per 1.0 ×
107 cells. Following electrotransfection by two 1.0-kV/cm
50-µs pulses separated by 500 ms, we matured the cells for
three days and measured eGFP fluorescence. While con-
trol cells (electroporated without mRNA) showed only
background fluorescence, the cells electrotransfected with
eGFP-mRNA fluoresced due to the presence of the eGFP
protein (Figure 3). Thus, DCs can translate exogenous
electrotransfected mRNA.
Dendritic cell characteristics during manufacturing
The percentage of CD14+ cells isolated from apheresis
products, purity of isolated CD14+  cells, efficiency of
CD14+ cell selection as well as viability and yield of IDCs
were indistinguishable between melanoma patients and
normal volunteer blood donors used as control [23].
However, the percentage of CD83+ DCs matured from
melanoma-patient derived cells was lower than in identi-
cally treated cells derived from patients suffering from
chronic myelogenous leukemia [23]. The relative paucity
of CD83+ melanoma-patient derived DCs was not due to
electrotransfection, as the percentage of electrotransfected
CD83+ DCs did not differ from untreated controls (p =
0.63).
Figure 4 summarizes the data for HLA-A, B, C, HLA-DC,
CD40, CD54, CD80, CDCD83, CD86 CD209 and CCR7
molecule expression by normal MDCs and native and
electrotransfected MDCs from melanoma patients. These
data show that patients' MDCs were similar to normal
MDCs and that mRNA electrotransfection did not affect
MDC membrane molecule expression to any major
extent.
Expression of CD83 (left) and CD86 (right) by patients'  RNA-transfected DCs (red) used for vaccination Figure 5
Expression of CD83 (left) and CD86 (right) by 
patients' RNA-transfected DCs (red) used for vacci-
nation. Isotype controls are shown in green.
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Expression of surface molecules by patients' dendritic cells Figure 4
Expression of surface molecules by patients' den-
dritic cells. Flow cytometric characterization of pertinent 
membrane molecules expressed by normal MDCs (n = 4; 
open columns) and cells from melanoma patients (n = 6): 
IDCs (light shade), MDCs (medium shade) and electrotrans-
fected MDCs (dark shade; for CD83 and CD86, n = 6; other 
molecules were measured in the cells from Patient 1 and 
Patient 5 only). Shown are mean values ± standard deviation.
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Table 5: Patient characteristics
Pt No. Age Gender Disease stage
1 52 F M1a
2 52 F M1a
3 66 M M1a
4 49 M M1a
5 40 M M1c
6 63 F M1cJournal of Translational Medicine 2006, 4:35 http://www.translational-medicine.com/content/4/1/35
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While electrotransfection did not affect membrane mole-
cule expression, they did reduce the yield of MDCs; no
more than 28.6 ± 16.1 percent of IDCs were recovered as
MDCs (in comparison to 70.1 ± 10.6 percent of normal,
not electroporated cells) reducing the DC recovery from
CD14+ cells to 9.8 ± 3.7 percent (in comparison to 22.9 ±
6.7 percent of normal cells; p = 0.003 for both). Immedi-
ately after electrotransfection, viability did not differ from
normal cells (91.2 ± 4.9 percent v. 95.6 ± 4.5 percent), but
after 24 hours viability was reduced. In addition, the pro-
cedure reduced the post-thaw viability of the cryopre-
served product in comparison to nonelectroporated
controls (69 ± 12 percent v. 82 ± 12 percent, p = 0.011).
Clinical end-points
The clinical protocol accrued a total of six patients with
stage IV melanoma (Table 5). Following debulking sur-
gery, the tumor was measurable in three patients, evalua-
ble in two and completely resected in one patient. Prior to
DC therapy two patients were treated by radiation and
three with interleukin 2.
The primary clinical goal of this phase 1 study was to eval-
uate the feasibility, safety and toxicity of an autologous
MDC vaccine, electrotransfected with in vitro amplified
autologous tumor-derived genomic mRNA, injected into
patients with metastatic melanoma. Figure 5 shows the
CD83 and CD86 expression histograms measured in
RNA-transfected DCs used for vaccination as part of indi-
vidual batch release data. The vaccine was safe and non-
toxic (no grade 3 or 4 toxicity) with a number of minor
(grade 1 and 2) side effects summarized in Table 6. A secondary endpoint of this study was the description of
clinical efficacy outcomes in the treated patients. None of
Functional potential of patients' dendritic cells and T cells Figure 6
Functional potential of patients' dendritic cells and T 
cells. (A) Proliferation of allogeneic T cells (pooled in equal 
amounts from four healthy donors) stimulated by MDCs 
from Patient 1–6 (full symbols) and normal MDCs (open 
symbols); (B) Proliferation of patients' T cells (full symbols) 
and normal T cells (open symbols) in response to stimulation 
by normal allogeneic MDCs pooled in equal amounts from 
four normal donors; (C) Interferon-γ secretion by patients' T 
cells (full symbols) and normal T cells (open symbols) upon 
stimulation by autologous MDCs previously pulsed with an 
influenza vaccine in vitro. Horizontal lines stand for mean val-
ues (longer lines) ± standard deviation.
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Table 6: Summary of maximum adverse events during dendritic 
cell treatment and follow-up
Adverse event Grade 1 Grade 2
Fatigue 1 (1) 1 (1)
Nausea 1 (2) 1 (1)
Anorexia 1 (1)
Arthralgia 1 (1)
Confusion 1 (1)
Diarrhea, colostomy 1 (1)
Diarrhea, no colostomy 1 (2)
Hemorrhage 1 (2)
Injection site Rxn 1 (1)
Myalgia 1 (1)
Pain-abdominal 1 (2)
Pain-bone 1 (1)
Speech 1 (1)
Vomiting 1 (1)
Wound, infectious 1 (1)
Numbers in parentheses indicate the cycle of vaccination when the 
adverse event occurred. No grade 3 or Grade 4 adverse reactions 
were observed.Journal of Translational Medicine 2006, 4:35 http://www.translational-medicine.com/content/4/1/35
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the five patients with measurable or evaluable disease
experienced an objective clinical response. Of these five
patients, one progressed prior to first vaccine injection,
one patient progressed at the second injection, two
patients progressed at the third injection and one patient
remained on study with stable disease. The single patient
without assessable disease progressed at the third injec-
tion.
To assess the functional potential of patients' immune
cells, we measured the ability of their ex vivo matured
MDCs to stimulate normal allogeneic T cells in vitro and
the in vitro responsiveness of their T cells to stimulation by
normal allogeneic MDCs. In preliminary experiments we
compared the ability of normal MDCs electrotransfected
with amplified mRNA and native (not electroporated)
MDCs to stimulate allogeneic MLR; we found that electro-
transfection did not affect the ability of the cells to stimu-
late proliferation of allogeneic T cells (data not shown).
Similarly, patients' MDCs stimulated the proliferation of
allogeneic T cells as effectively as normal MDCs (p = 0.72;
Figure 6A) and patients' T cells responded to stimulation
by normal allogeneic MDCs as effectively as normal T cells
(p = 0.35; Figure 6B). In addition, patients' DCs pulsed in
vitro with an influenza vaccine were as effective in stimu-
lating autologous T cells to secrete interferon-γ as were the
corresponding normal DC/T-cell combinations (p = 0.75;
Figure 6C). Thus, MDCs and T cells isolated from stage IV
melanoma patients can mature and respond to stimula-
tion similarly to normal cells.
We monitored the response of T cells, isolated from
patients' blood at different times during treatment, for
response to immunization. We measured the prolifera-
tion of and interferon-γ release by patients' T cells upon
introduction of DCs used for immunization but in no case
did we observe any immune response that could be attrib-
uted to DC therapy.
Discussion
Immunotherapy holds the promise of contributing to the
limited treatment options available to patients suffering
from metastatic melanoma. For active immunization
against the disease, DCs are considered advantageous
because of their ability to stimulate naïve T cells as well as
the memory cells [28]. In addition, the use of whole
tumor cells, cell lysates, cell fractions and transcripts as
antigens in "education" of DCs for presentation of tumor-
associated antigens allows clinical studies without the
need for patient selection based on their HLA make-up as
is the case in the studies employing chemically defined
epitopes (cf. refs. 1, 2 and references therein).
We conducted the present study to determine whether
mRNA extraction, in vitro expansion and electrotransfec-
tion into DCs are feasible in the setting of a clinical trial
and safe for patients. While previously we reported a pre-
liminary characterization of DC phenotype and viability
[23], here we demonstrate that pertinent transcripts of
tumor-associated antigens can be detected following
transfection of ex vivo expanded mRNA into DCs. Thus,
this method for preparing clinical-grade DCs is feasible
and the resulting cellular vaccine is safe. That we observed
neither clinical effects nor immune effects of DCs treat-
ment may not be surprising in view of the severity of dis-
ease, limited number of vaccinations and short life
expectancy of the patients. Namely, only one patient lived
long enough to have received the entire course of therapy
while three patients received just two courses of vaccina-
tion. Clearly, the next phase of the clinical study will have
to be conducted with patients harboring lower tumor bur-
dens and overall in better health, in line with the prevail-
ing thinking that immunotherapy might be most effective
within the setting of minimal residual disease.
Recently, Kyte and colleagues evaluated a clinical scale
and clinical grade procedure for preparation of DCs trans-
fected with unamplified native melanoma-derived mRNA
[21]. Their exemplary study allows a comparison of the
effects of the transfected native mRNA and amplified
mRNA on myeloid DCs. Distribution of molecular sizes
in the total RNA isolated in this study (Figure 1B) is simi-
lar to the results of Kyte et al. [21] who purified mRNA on
poly-T beads with the result of enriching the fraction of
lower molecular weight mRNA relative to total RNA. We
obtained a similar enrichment of lower molecular weight
mRNA by in vitro expansion. Thus, it appears that both
methods yielded qualitatively similar products. Conse-
quently, the less demanding poly-T mediated isolation of
native mRNA is advantageous when amounts and quality
of the tumor tissue, i.e., total RNA, are adequate. On the
other hand, the more demanding in vitro expansion may
be advantageous when the availability of tumor tissue is
limited and/or when larger amounts of RNA are needed.
Although we demonstrated that the transcripts of antigens
of interest are maintained throughout expansion, the
complexity of this technically demanding procedure
increases the possibility of failure.
DCs transfected with amplified mRNA retain similarly
high viability as non-electroporated cells [23] and cells
transfected with defined plasmids (e.g., for green fluores-
cent protein and proteinase 3; results not shown) or puri-
fied mRNA [21]. However, upon freezing and thawing,
DCs transfected with amplified mRNA appeared less via-
ble. This effect does not appear to be caused by electro-
transfection alone but may be facilitated by the effects of
advanced melanoma on DC precursors. Elucidation of the
reasons for the reduced recovery of thawed cells requires
further study, but it is possible that some in vitro amplifiedJournal of Translational Medicine 2006, 4:35 http://www.translational-medicine.com/content/4/1/35
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RNA species interfered with recovery. Whatever the cause,
reduced cell recovery and viability limit DC manufactur-
ing for clinical trials in advanced melanoma. A possible
solution may lie in the recent demonstration that electro-
transfecting mature DCs results in high yields of viable and
functional DCs [6].
In conclusion, tumor-specific vaccination with DCs trans-
fected with in vitro amplified tumor-borne mRNA is tech-
nically feasible. In the first clinical trial utilizing this
technology, we have shown that such immunization is
safe. The inherent advantage of this and similar methods
is that they are likely to vaccinate against the broad spec-
trum of tumor-borne antigens that may reduce the ability
of tumors to escape immunity by virtue of their genetic
instability.
Acknowledgements
This work was supported by Mayo Clinic Comprehensive Cancer Center 
Support Grant CA-15083. Stem Cell Laboratory has been supported by 
Mrs. Adelyn L. Luther, Singer Island, Florida; Commonwealth Cancer Foun-
dation for Research, Richmond, Virginia, and Glen and Florence Voyles 
Foundation, Terre Haute, Indiana. We thank Dr. Alan D. King and Mr. Rich-
ard E. Walters, Cyto Pulse Sciences, Inc., for electroporation equipment, 
supplies and helpful advice and Drs. Franklyn G. Prendergast and S. Brean-
ndan Moore for continuing interest and support.
References
1. Banchereau J, Palucka AK: Dendritic cells as therapeutic vac-
cines against cancer.  Nature Rev Immunol 2005, 5:296-306.
2. Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM: Dendritic cell
immunotherapy: mapping the way.  Nature Med 2004,
10:475-480.
3. Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD,
Sampson JH: The history, evolution, and clinical use of den-
dritic cell-based immunization strategies in the therapy of
brain tumors.  J Neuro-Oncol 2003, 64:161-176.
4. Gilboa E, Vieweg J: Cancer immunotherapy with mRNA-trans-
fected dendritic cells.  Immunol Rev 2004, 199:251-263.
5. Liao X, Li Y, Bonini C, Nair S, Gilboa E, Greenberg PD, Yee C: Trans-
fection of RNA encoding tumor antigens following matura-
tion of dendritic cells leads to prolonged presentation of
antigen and the generation of high-affinity tumor-reactive
cytotoxic T lymphocytes.  Mol Ther 2004, 9:757-764.
6. Schaft N, Dorrie J, Thumann P, Beck VE, Muller I, Schultz ES, Kampge
E, Dieckmann D, Schuler G: Generation of an optimized polyva-
lent monocyte-derived dendritic cell vaccine by transfecting
defined RNAs after rather than before maturation.  J Immunol
2005, 174:3087-3097.
7. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG,
Fleming ID, Gershenwald JE, Houghton AJ, Kirkwood JM, McMasters
KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thomp-
son JA, Thompson JF: Final version of the American Joint Com-
mittee on Cancer staging system for cutaneous melanoma.
J Clin Oncol 2001, 19:3635-3648.
8. National Cancer Institute: Surveillance, epidemiology and end
results database.   [http://www.seer.cancer.gov/statfacts/html/
melan/html?statfacts_page=melan.hjtml&x-8&y=12 ].
9. Rosenberg SA: Progress in human tumour immunology and
immunotherapy.  Nature 2001, 411:380-384.
10. Rosenberg S: Lymphokine-activated  killer cells: a new
approach to immunotherapy of cancer.  J Natl Cancer Inst 1985,
75(4):595-603.
11. Wolchok JD, Livingston PO: Vaccines for melanoma: translating
basic immunology into new therapies.  Lancet Oncol 2001,
2:205-211.
12. High WA, Stewart D, Wilbers CRH, Cockerell CJ, Hoang MP, Fitz-
patrick JE: Completely regressed primary cutaneous malig-
nant melanoma with nodal and/or visceral metastases:  A
report of 5 cases and assessment of the literature and diag-
nostic criteria.  J Am Acad Derm 2005, 53:89-100.
13. Lotze MT, Shurin M, Davis I, Amoscato A, Storkus WJ: Dendritic
cell based immunotherapy of cancer.  Adv Exp Med Biol 1997,
417:551-569.
14. Ingram SB, O'Rourke MG: DC therapy for metastatic
melanoma.  Cytotherapy 2004, 6:148-153.
15. Nestle FO, Banchereau J, Hart D: Dendritic cells: On the move
from bench to the bedside.  Nature Med 2001, 7:761-765.
16. Boczkowski D, Nair S, Snyder D, Gilboa E: Dendritic cells pulsed
with RNA are potent antigen-presenting cells in vitro and in
vivo.  J Exp Med 1996, 184:465-472.
17. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone
marrow-generated dendritic cells pulsed with tumor
extracts or tumor RNA induce antitumor immunity against
central nervous system tumors.  J Exp Med 1997,
186:1177-1182.
18. Saeboe-Larssen S, Fossberg E, Gaudernack G: mRNA-based elec-
trotransfection of human dendritic cells and induction of
cytotoxic T lymphocyte responses against the telomerase
catalytic subunit (hTERT).  J Immunol Meth 2002, 259:191-203.
19. van Tendeloo VFI, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van
Broeckhoven C, Van Bockstaele DR, Berneman ZN: Highly effi-
cient gene delivery by mRNA electroporation in human
hematopoietic cells: superiority to lipofection and passive
pulsing of mRNA and to electroporation of plasmid cDNA
for tumor antigen loading of dendritic cells.  Blood 2001,
98:49-56.
20. Lohmann S, Galle K, Knop J, Enk AH: CD83+ human dendritic
cells transfected with tumor peptide cDNA by electropora-
tion induce specific T-cell responses: A potential tool for
gene immunotherapy.  Cancer Gene Ther 2000, 7:605-614.
21. Kyte JA, Kvalheim G, Aamdal S, Saeboe-Larssen S, Gaudernack G:
Preclinical full-scale evaluation of dendritic cells transfected
with autologous tumor-mRNA for melanoma vaccination.
Cancer Gene Ther 2005, 12:579-591.
22. Padley DJ, Dietz AB, Gastineau DA, Vuk-Pavlovic S: Mature mye-
loid dendritic cells for clinical use prepared from CD14-pos-
itive cells isolated by immunomagnetic adsorption.  J
Hematother Stem Cell Res 2001, 10:427-429.
23. Dietz AB, Padley DJ, Butler GW, Maas ML, Greiner CW, Gastineau
DA, Vuk-Pavlovic S: Clinical-grade manufacturing of dendritic
cells from CD14+ precursors: Experience from phase 1 clin-
ical trial in chronic myelogenous leukemia and malignant
melanoma.  Cytotherapy 2004, 6:563-570.
24. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E: Induction of
tumor immunity and cytotoxic T lymphocyte responses
using dendritic cells transfected with messenger RNA ampli-
fied from tumor cells.  Cancer Res 2000, 60:1028-1034.
25. Therasse P, Arbuck S, Eisenhauer EA, Wanders J, Kaplan RS, Rubin-
stein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC,
Gwyther SG: New guidelines to evaluate the response to
treatment in solid tumors. European Organization for
Research and Treatment of Cancer, National Cancer Insti-
tute of the United States, National Cancer Institute of Can-
ada.  J Natl Cancer Inst 2000, 92:205-216.
26. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer
C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0:
development of a comprehensive grading system for the
adverse effects of cancer treatment.  Sem Rad Oncol 2003,
13:176-181.
27. March JC, Rao G, Bentley WE: Biotechnological applications of
green fluorescent protein.  Appl Microbiol Biotechnol 2003,
62:303-315.
28. Banchereau J, Steinman RM: Dendritic cells and the control of
immunity.  Nature 1998, 392:245-252.
29. Feroze-Merzoug F, Berquin IM, Dey J, Chen YQ: Peptidylprolyl iso-
merase A (PPIA) as a preferred internal control over
GAPDH and beta-actin in quantitative RNA analyses.  Biotech-
niques 2002, 32:776-782.
30. Bernsen MR, Dijkman HBPM, de Vries E, Figdor CG, Ruiter DJ,
Adema GJ, van Muijen GN: Identification of multiple mRNA andPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Translational Medicine 2006, 4:35 http://www.translational-medicine.com/content/4/1/35
Page 13 of 13
(page number not for citation purposes)
DNA sequences from small tissue samples isolated by laser-
assisted microdissection.  Lab Investig 1998, 78:1267-1273.